Takeda acquires TAK-101 license from COUR in $420m deal

Takeda acquires TAK-101 license from COUR in $420m deal

Submitted by admin on October 23, 2019 - 10:16am
Source: 
Pharmaceutical Business Review
News Tags: 
Takeda
COUR Pharmaceutical Development
CNP-101
TAK-101
celiac disease
Headline: 
Takeda acquires TAK-101 license from COUR in $420m deal
snippet: 


Takeda Pharmaceutical has signed a deal worth up to $420m with COUR Pharmaceutical Development to acquire an exclusive global license to develop and commercialise the latter’s CNP-101 (TAK-101).

Do Not Allow Advertisers to Use My Personal information